About Bruker Cellular Analysis
Bruker Cellular Analysis is a company based in New Haven (United States) founded in 2012 was acquired by Berkeley Lights in December 2022. It operates as a Technology-as-a-Service and Professional Services. Bruker Cellular Analysis has raised $185.85 million across 16 funding rounds from investors including KeyBank, NIH and BlackRock. The company has 195 employees as of December 31, 2022. Bruker Cellular Analysis offers products and services including Beacon Discovery™, IsoLight System, and T Cell Profiling Kit. Bruker Cellular Analysis operates in a competitive market with competitors including 10X Genomics, Guardant Health, Foundation Medicine, ArcherDX and Natera, among others.
- Headquarter New Haven, United States
- Employees 195 as on 31 Dec, 2022
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Bruker Cellular Analysis
-
Annual Revenue
$16.76 M (USD)-3as on Dec 31, 2022
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$185.85 M (USD)
in 16 rounds
-
Latest Funding Round
$92.5 M (USD), Series D
Jan 07, 2021
-
Investors
KeyBank
& 15 more
-
Employee Count
195
as on Dec 31, 2022
-
Acquired by
Berkeley Lights
(Dec 21, 2022)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Bruker Cellular Analysis
Bruker Cellular Analysis offers a comprehensive portfolio of products and services, including Beacon Discovery™, IsoLight System, and T Cell Profiling Kit.
Live single-cell analysis is enabled for research purposes.
Single-cell proteomic signatures are captured for analysis purposes.
T cell functions are profiled for therapeutic discovery.
People of Bruker Cellular Analysis
Unlock access to complete
Unlock access to complete
Software Development Team
43 people
Leadership Team
37 people
Finance and Accounting
29 people
Sales and Marketing
29 people
Legal and Compliance
13 people
Field Team
11 people
Senior Team
10 people
Accounts Team
8 people
Unlock access to complete
Funding Insights of Bruker Cellular Analysis
Bruker Cellular Analysis has successfully raised a total of $185.85M across 16 strategic funding rounds. The most recent funding activity was a Series D round of $92.5 million completed in January 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Bruker Cellular Analysis
Bruker Cellular Analysis has secured backing from 16 investors, including venture fund and institutional investors. Prominent investors backing the company include KeyBank, NIH and BlackRock.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Health-tech companies are targeted for venture capital investments.
|
Locked | Locked | Locked | |
|
Private equity and hedge fund investments in healthcare are managed.
|
Locked | Locked | Locked | |
|
Venture capital firm investing in life sciences & tech sectors
|
Locked | Locked | Locked |
Investor details for Bruker Cellular Analysis
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Bruker Cellular Analysis
Investment portfolio details for Bruker Cellular Analysis
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Bruker Cellular Analysis
Detailed financials for Bruker Cellular Analysis
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Bruker Cellular Analysis Comparisons
Peer comparison for Bruker Cellular Analysis
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Bruker Cellular Analysis
Bruker Cellular Analysis operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as 10X Genomics, Guardant Health, Foundation Medicine, ArcherDX and Natera, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Instrument systems for genomic research and sequencing libraries are developed.
|
|
| Locked | Locked | Locked |
Digital sequencing technology for cancer detection is developed.
|
|
| Locked | Locked | Locked |
Genomics-based diagnostic tests for cancer are provided.
|
|
| Locked | Locked | Locked |
Molecular cancer diagnostic products are developed using patented AMP technology.
|
|
| Locked | Locked | Locked |
Developer of cell-free DNA testing for oncology, women’s health, and organ health
|
|
| Locked | Locked | Locked |
Provider of omics-based solutions for clinical genomics, systems biology, and drug discovery
|
Detailed competitors of Bruker Cellular Analysis
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Bruker Cellular Analysis
Complete news archive for Bruker Cellular Analysis
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Bruker Cellular Analysis
Bruker Cellular Analysis was founded in 2012 and raised its 1st funding round 2 years after it was founded.
Bruker Cellular Analysis is headquartered in New Haven, United States. It is registered at New Haven, Connecticut, United States.
Bruker Cellular Analysis is a funded company, having raised a total of $185.85M across 16 funding rounds to date.
As of Dec 31, 2022, the latest employee count at Bruker Cellular Analysis is 195.
Annual revenue of Bruker Cellular Analysis is $16.76M as on Dec 31, 2022.
Bruker Cellular Analysis is engaged in pioneering live single-cell, multimodal, and temporal functional analysis to accelerate scientific breakthroughs. Solutions are provided for antibody discovery, T cell profiling, and cell line development in the optofluidic domain. Proteomic barcoding tools are offered to capture cytokine and phosphoprotein signatures for disease prediction. The company serves sectors like cancer immunology, cell and gene therapy, infectious diseases, inflammation, neurology, and oncology. Platforms such as Beacon Discovery and IsoLight are designed for academic, translational, and biotech research labs.
Bruker Cellular Analysis's top competitors include Guardant Health, Strand Life Sciences and Foundation Medicine.
Bruker Cellular Analysis offers Beacon Discovery™, IsoLight System, and T Cell Profiling Kit.
Bruker Cellular Analysis has 16 investors. Key investors include KeyBank, NIH, BlackRock, Yale University, and Berkeley Lights.